Complaints that Pfizer’s antiviral medication used to treat COVID in high-risk patients generate rebound symptoms have plagued the drug’s reputation. In a new report, the FDA states that rebound also happens in individuals who did not take paxlovid, which can prevent COVID from becoming severe if administered early enough and appears to be a part of the illness process in some cases. The FDA evaluated Pfizer’s paxlovid clinical trials before an advisory committee meeting to determine whether to recommend the drug’s full approval.